Dermatologic Therapy最新文献

{"title":"Intradermal Autologous Mesenchymal Stem Cell Microblocks (TRTP-101) as an Initial-Stage Organoid for Atrophic Scars: A First-In-Human Phase I Single-Dose Pilot Study With Long-Term Follow-Up","authors":"Yeonju Lee,&nbsp;Junesoo Jeon,&nbsp;Se Jin Oh,&nbsp;Jihye Park,&nbsp;Hye Jung Park,&nbsp;Eun Ji Kim,&nbsp;Jaejin Cho,&nbsp;Jong Hee Lee","doi":"10.1155/dth/1918169","DOIUrl":"https://doi.org/10.1155/dth/1918169","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>TRTP-101 is a novel regenerative therapy consisting of autologous adipose-derived mesenchymal stem cells (ADMSCs) formed into three-dimensional (3D) microtissues (microblocks, MiBs). The living 3D MiBs are designed to be extracellular matrix–enriched and organoid/tissue-like, supporting sustained trophic signaling following intradermal delivery for atrophic scars.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study was conducted to assess the safety and tolerability of TRTP-101 in adults with atrophic scars.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this first-in-human, Phase I, single-arm pilot study, adults (≥ 19 years) with atrophic scars meeting prespecified criteria underwent autologous adipose harvest from the abdomen and subsequent intradermal administration of TRTP-101 (1 × 10⁷ cells/mL; up to 0.2 mL per scar) into four target scars per participant. Safety was the primary endpoint. Exploratory efficacy was assessed using percentage change in depression volume measured by 3D image analysis at Weeks 1, 4, 8, 12, and 24, with follow-up extending up to 1 year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three participants received TRTP-101 and completed 1-year follow-up. No dose-limiting toxicities, treatment-related adverse events, or late-onset reactions were observed throughout the follow-up period. The mean percentage reductions in atrophic scar volume were 21.27%, 19.72%, 18.88%, and 26.60% at Weeks 1, 4, 8, and 12, respectively, with a mean reduction of 19.31% at 1 year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A single intradermal administration of TRTP-101 was well tolerated throughout 1 year and showed early, quantifiable reductions in scar depression volume, with a mean reduction still observed at 1 year. This first-in-human study may provide preliminary support for the safety and potential regenerative role of autologous ADMSC-derived 3D MiBs for atrophic scars and supports further controlled clinical evaluation.</p>\u0000 \u0000 <p><b>Trial Registration</b>: ClinicalTrials.gov NCT06210919 (first posted January 18, 2024) and NCT06435884 (first posted May 30, 2024)</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1918169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148942734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Targeted Systemic Therapies in Head and Neck Atopic Dermatitis: A Systematic Review and Meta-Analysis","authors":"Maha Mohammed Alkharisi,&nbsp;Abdullah Mohammed Almeziny,&nbsp;Raghad Saud AlOubili,&nbsp;Fahad Khalid Almalik,&nbsp;Mishari Tariq Alrubaiaan,&nbsp;Abdulaziz Abdullah Almohanna,&nbsp;Mohammed Salem Alshehri,&nbsp;Alanoud Alsalman,&nbsp;Fares Alkhayal","doi":"10.1155/dth/8183604","DOIUrl":"https://doi.org/10.1155/dth/8183604","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A distinctive and difficult phenotype, head and neck atopic dermatitis (AD) is linked to a higher disease burden and inconsistent treatment response. The effectiveness of targeted systemic therapy in this field is currently little understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate both the safety and effectiveness of targeted systemic therapies for individuals’ AD affecting the head and neck, such as tralokinumab, dupilumab, and upadacitinib.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A meta-analysis and systematic review were conducted using PRISMA guidelines. In three databases (PubMed, Web of Science, and EMBASE), we searched for relevant research. The qualifying research included observational studies and randomized controlled trials that reported outcomes among patients with head and neck involvement. The primary findings included the head and neck Eczema Area and Severity Index (H&amp;N EASI-75) and the percentage change in EASI. The Numerical Rating Scale for pruritus, the Dermatology Life Quality Index for quality of life, and safety outcomes were secondary results. The meta-analysis was conducted using a random-effects model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twelve studies were included. The pooled H&amp;N EASI-75 response rate was 51% (95% CI: 40–62), with a mean percentage reduction in EASI of −72.86% (95% CI: −78.98 to −66.74). Significant improvements were observed in pruritus (mean change −4.38) and quality of life (−9.97). Across indirect, between-study subgroup comparisons, studies of upadacitinib showed numerically greater effect estimates than studies of dupilumab or tralokinumab; in the absence of head-to-head trials, these comparisons are hypothesis-generating rather than definitive. The overall prevalence of adverse events was 48%, with conjunctivitis (7%) and herpes zoster (2%) reported. Substantial heterogeneity was noted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Targeted systemic therapies were associated with clinically meaningful improvements in head and neck AD, although substantial heterogeneity and the indirect nature of the drug-specific comparisons warrant cautious interpretation. Differences in efficacy and safety profiles across agents highlight the importance of individualized treatment selection, and further head-to-head comparative studies are warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8183604","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148942643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Androgenetic Alopecia Severity and Cardiovascular Risk in a Mixed-Race Population: A Cross-Sectional Study Using the Hamilton–Norwood Scale and Framingham Score","authors":"Mara Diane Lisboa Tavares Mazzillo,&nbsp;Sueli Coelho da Silva Carneiro","doi":"10.1155/dth/7980452","DOIUrl":"https://doi.org/10.1155/dth/7980452","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Androgenetic alopecia (AGA) has been suggested as a clinical marker of cardiovascular risk, but the strength of this association remains uncertain, especially in mixed-race populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the relationship between AGA severity, classified by the Hamilton–Norwood scale, and cardiovascular risk estimated by the Framingham Risk Score in an admixed population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cross-sectional study including 152 men with AGA and 151 age- and sex-matched controls, conducted in a dermatology outpatient setting. AGA severity was classified using the Norwood scale (Grades III–VII). Cardiovascular risk was categorized as low (&lt; 10%), moderate (10%–20%), or high (&gt; 20%) with the Framingham Risk Score. Associations were tested with chi-square and Cramér’s V.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Norwood grades among AGA patients were as follows: III (19.1%), IV (16.4%), V (22.4%), VI (13.8%), and VII (28.3%). The study population was admixed: White (37.5% AGA vs. 49.4% controls), Black (19.1% vs. 8.6%), and Brown (43, 4% vs. 38.3%); Asian participants were absent in the AGA group but represented 3.7% of controls. Cardiovascular risk in AGA patients was low in 59.2%, moderate in 21.1%, and high in 19.7%. High cardiovascular risk was significantly more prevalent (<i>p</i> = 0.0026) in AGA patients (53.3%) than controls (13.3%). Hypertension, diabetes, and smoking were also more frequent in the AGA group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Increasing AGA severity was associated with higher cardiovascular risk. AGA may serve as a simple clinical marker to prompt early cardiovascular assessment and preventive strategies. In this mixed population, AGA was more common among Black individuals, suggesting potential ethnic-related vulnerability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7980452","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148942197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intramuscular Compound Betamethasone for the Treatment of Telogen Effluvium: A Single-Center Real-World Study","authors":"Wei Tu,&nbsp;Mang Sun,&nbsp;Jie-Zhi Zhang,&nbsp;Qin-Si Liu,&nbsp;Wen-Wen Zhou,&nbsp;Heng-Guang Zhao","doi":"10.1155/dth/5627316","DOIUrl":"https://doi.org/10.1155/dth/5627316","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Telogen effluvium is a common diffuse nonscarring alopecia that can cause substantial psychological distress, while currently available treatments are often slow to provide symptom relief.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a retrospective single-center analysis of 149 patients with TE treated between January 2023 and December 2025. Patients received intramuscular injections of compound betamethasone. Outcomes extracted from medical records included early treatment response, time to symptom improvement, duration of effect, recurrence-free intervals, and adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean patient age was 33.5 ± 9.0 years, and 98.0% were female. A chronic disease course was present in 73.8% of patients. After the first injection, 38.9% of patients achieved marked improvement without an immediate need for further injections, whereas most patients required repeated treatment. A total of 40.0% of patients showed improvement within 7 days, followed by 14 days (26.7%) and 3 days (16.7%). The most frequently documented duration of benefit after a single injection was 21 days. Except for 3.3% of the patients experiencing menstrual disorders, no serious side effects were documented.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Limitations</h3>\u0000 \u0000 <p>This was a retrospective, single-center study without a control group. The efficacy outcomes rely largely on patient-reported improvement in hair shedding, without standardized objective measurements, and detailed onset and duration data were available for only a subset of treated patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Intramuscular compound betamethasone may provide a rapid short-term reduction in hair shedding in selected patients with TE and may be a useful adjunctive option in chronic or recurrent disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5627316","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148942225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Nomogram Incorporating Cumulative Treatment Sessions for Complete Clearance of Port-Wine Stains Receiving Sequential PDL Therapy: Development and Temporal External Validation","authors":"Anqi Yang,&nbsp;Yansong Lu,&nbsp;Jun Niu","doi":"10.1155/dth/3855750","DOIUrl":"https://doi.org/10.1155/dth/3855750","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background and Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Port-wine stain (PWS) is a congenital capillary malformation with highly variable response to pulsed dye laser (PDL) therapy. This study developed and temporally validated a prognostic model incorporating cumulative treatment exposure, presented as a nomogram, to estimate the probability of complete lesion clearance for patient counseling.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We conducted a single-center retrospective cohort study including 823 treatment-naive Chinese patients with PWS who had completed ≥ 2 PDL sessions with ≥ 6 months of follow-up between August 2010 and June 2022. An independent temporal external validation cohort of 134 consecutive patients treated from July 2022 to June 2025 was analyzed retrospectively. Treatment response was graded using a four-point ordinal scale. Generalized ordered logistic regression was used to identify determinants across the full response spectrum, and a binary logistic model was constructed specifically for complete clearance prediction. Internal and temporal external validations were performed to evaluate model performance.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Five clinical factors were identified as independent predictors of complete lesion clearance: cumulative completed treatment sessions (aOR 1.281), lesion area (aOR 0.976 per cm&lt;sup&gt;2&lt;/sup&gt;), lesion color grade (aOR 0.468 per grade), sex, and age. The anatomical site was nonsignificant across all subgroups (all global &lt;i&gt;p&lt;/i&gt; &gt; 0.05). All significant predictors except cumulative completed treatment sessions exhibited threshold-varying effects in the partial proportional odds model for ordinal treatment efficacy grade. The final prognostic model incorporating cumulative treatment exposure showed good apparent discriminative performance (AUC 0.748) in the derivation cohort. Bootstrap resampling (&lt;i&gt;B&lt;/i&gt; = 500) yielded an optimism-corrected AUC of 0.739, and performance was further validated in an independent temporal external cohort (AUC 0.789).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We constructed a nomogram for static prognostic assessment following PDL therapy in patients with PWS who had completed ≥ 2 sessions with ≥ 6 months of follow-up. This prognostic model, incorporating cumulative treatment exposure and routinely collected clinical predictors, estimates the probability of complete lesion clearance to support prognostic counseling. Both optimism-corrected internal and independent temporal external validation demonstrated satisfactory discrimination. Prospective va","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3855750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous Fascial Microenvironment in Skin Scar Formation: Mechanisms and Therapeutic Strategies","authors":"Qixuan Wu,&nbsp;Chak Kwong Cheng,&nbsp;Yanyan Zhang,&nbsp;Tingrui Han,&nbsp;Wentao Wang,&nbsp;Siyang Deng,&nbsp;Zhu Li,&nbsp;Linxuan Wu,&nbsp;Cuiping Wei","doi":"10.1155/dth/1205463","DOIUrl":"https://doi.org/10.1155/dth/1205463","url":null,"abstract":"<p>Subcutaneous fascia has attracted increasing attention as a possible contributor to deep cutaneous wound repair. Murine lineage-tracing and skin–fascia chimera studies suggest that fascia-associated fibroblasts and pre-existing extracellular matrix can be mobilized into the wound bed, where they contribute to matrix deposition and wound contraction. How far these findings apply to human pathological scars, however, remains uncertain. Hypertrophic scars and keloids are distinct disorders, and their development reflects the combined effects of mechanical tension, persistent inflammation, endothelial dysfunction, fibroblast heterogeneity, genetic susceptibility, and anatomical site. At present, there is no direct evidence that fascia-derived fibroblasts are the main cellular source of human keloids. In this review, we examine the evidence for fascia involvement alongside the broader literature on human scar biology. We also discuss several fascia-related therapeutic targets, including retinoic acid signaling, HIF-1<i>α</i>, p120-catenin, N-cadherin, and connexin 43. Most of these approaches are supported mainly by cell and animal studies, and their clinical value remains to be established. Fascia is therefore best viewed as one context-dependent component of scar formation rather than a universal explanation for pathological scarring.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1205463","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Demographics, Clinical Characteristics, Treatment Patterns, and Burden of Atopic Dermatitis in Patients Initiating Dupilumab: A Retrospective, Observational Study Using Data From a Real-World Registry (CORNERSTONE)","authors":"Jiahui Zhao,&nbsp;Dan Shen,&nbsp;Mingxiao Chen,&nbsp;Joshua Zhang,&nbsp;Ruoyu Li,&nbsp;Yang Wang,&nbsp;Hang Li","doi":"10.1155/dth/4711988","DOIUrl":"https://doi.org/10.1155/dth/4711988","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chinese atopic dermatitis (AD) patients initiating dupilumab in real-world settings are not well characterized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To describe baseline characteristics of Chinese AD patients starting dupilumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a retrospective study utilizing real-world data from the observational registry of China Type 2 Inflammatory Skin Diseases, CORNERSTONE, for AD patients initiating dupilumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between August 2021 and July 2022, 3960 dupilumab users were identified (age: 1–96 years, male: 58.5%). Early-onset AD was noted in 13.2%, with common anatomic sites affected being the trunk, arm, and leg. Clinical phenotypes included typical flexural dermatitis (62.1%), inflammatory (20.2%), and xerosis (15.2%). Type 2 inflammatory comorbidities were present in 50.8%, with allergic rhinitis/sinusitis, food allergy, and bronchial asthma being most prevalent. Topical corticosteroids and antihistamines often precede and accompany dupilumab. Mean Eczema Area and Severity Index (EASI) score was 13.5, Body Surface Area (BSA) affected 29.7%, and Peak Pruritus Numerical Rating Scale (PP-NRS) 7.2. Infants’ Dermatitis Quality of Life index (IDQoL), Children’s Dermatology Life Quality Index (CDLQI), and Dermatology Life Quality Index (DLQI) scores were 16.9, 13.8, and 13.1 for patients &lt; 4, ≥ 4–&lt; 16, and ≥ 16 years, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In China, real-world AD patients initiating dupilumab exhibit a broad age spectrum and clinical characteristics, with multidimensional baseline disease burden.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4711988","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selection of Anesthesia for Surgical Resection of Facial Skin Tumors in Elderly Patients: A Retrospective Comparison of Wide-Awake Local Anesthesia and General Anesthesia","authors":"YiChun Ding,&nbsp;Hao Ding,&nbsp;Lin Zhang,&nbsp;XinYi Li,&nbsp;Fei Zhu,&nbsp;XiaoJing Li","doi":"10.1155/dth/9748414","DOIUrl":"https://doi.org/10.1155/dth/9748414","url":null,"abstract":"<p>With the increasing prevalence of facial skin tumors among aging populations and growing concerns regarding anesthesia-related risks in elderly surgical patients, this retrospective cohort study (March 2021–April 2025) evaluated the safety, clinical efficacy, and cost-effectiveness of wide-awake local anesthesia (WALA) compared to general anesthesia (GA) in 243 patients aged 65–90 years undergoing facial skin tumor resection. To mitigate selection bias, a propensity-score matching was performed and the final cohort included 196 patients with comprehensive analysis of perioperative parameters, postoperative complications, hospitalization duration, and total costs. Results demonstrated that WALA significantly reduced preoperative preparation time (12 ± 3.4 versus 35 ± 9.8 min, <i>p</i> &lt; 0.001), total hospitalization costs ($954 ± $187 versus $1480 ± $352, <i>p</i> &lt; 0.001), and length of stay (5.2 ± 1.8 versus 11.3 ± 3.7 days, <i>p</i> &lt; 0.001). Postoperative complications were markedly lower in the WALA group (2 versus 15 cases, <i>p</i> = 0.002), with no intensive care unit (ICU) admissions required compared to four in the GA group, while wound-healing outcomes remained comparable between groups. These findings indicate that WALA represents a safe, clinically effective, and economically advantageous alternative to GA for facial skin tumor resection in elderly patients, offering substantial benefits in reducing complications, shortening recovery, optimizing resource utilization, and enhancing perioperative safety without compromising surgical quality. This approach holds particular promise for improving care pathways in geriatric dermatologic surgery.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9748414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Ring Finger Paradox as a Predictor of Treatment Failure in Fingernail Onychomycosis: A Retrospective Cohort Study","authors":"Chatisa Panyawong,&nbsp;Sumanas Bunyaratavej,&nbsp;Penvadee Pattanaprichakul,&nbsp;Pattriya Jirawattanadon,&nbsp;Panitta Sitthinamsuwan,&nbsp;Panyapat Buranaporn,&nbsp;Pantaree Kobkurkul,&nbsp;Korakot Leelathanakorn,&nbsp;Waranyoo Prasong,&nbsp;Akkarapong Plengpanich,&nbsp;Lalita Matthapan,&nbsp;Charussri Leeyaphan","doi":"10.1155/dth/1300539","DOIUrl":"https://doi.org/10.1155/dth/1300539","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Fingernail onychomycosis differs clinically from toenail disease. While toenail onychomycosis has been extensively studied, research investigating demographic characteristics, histopathology, and causative organisms as prognostic factors for cure specifically in fingernail cases remains notably limited. Although prognostic factors for toenail onychomycosis have been extensively documented, these findings cannot be directly extrapolated to fingernail infections due to distinct environmental and occupational exposures. Consequently, conducting a direct comparative study between these two anatomical sites remains challenging and represents an important avenue for future research.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This retrospective cohort study aims to identify prognostic factors associated with the cure of fingernail onychomycosis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study included patients aged 18 years or older diagnosed with fingernail onychomycosis who underwent histopathological examination of nail specimens, excluding those with incomplete records. Clinical evaluation and laboratory investigation were studied. Descriptive statistics, chi-square tests, and independent &lt;i&gt;t&lt;/i&gt;-tests were utilized for data analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 45 patients (predominantly female, 71.1%) with a mean age of 48.0 ± 20.5 years were enrolled. Distal and lateral subungual onychomycosis and proximal subungual onychomycosis were found in 38 (84.4%) and 7 (15.6%) patients, respectively. Ring finger involvement (18 cases, 40.0%) was significantly associated with younger patients (&lt;i&gt;p&lt;/i&gt; = 0.003) and presented with periungual inflammation at the proximal nail fold (&lt;i&gt;p&lt;/i&gt; = 0.021). Thirteen cases (28.9%) failed to respond to standard systemic therapy. Within the population with ring finger involvement, the treatment failure rate was 55.6% (10 out of 18 cases). These nonresponders were significantly younger (&lt;i&gt;p&lt;/i&gt; = 0.014), more likely to have ring finger involvement (&lt;i&gt;p&lt;/i&gt; = 0.001) and presented with septate hyphae on histology (100.0%, &lt;i&gt;p&lt;/i&gt; = 0.010).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Onychomycosis of the ring finger in young patients was observed to be recalcitrant to treatment, suggesting that these cases may require closer monitoring or alternative therapeutic approaches in clinical practice. Histopathological features, including mold invasion","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1300539","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Therapeutic Potential of GLP-1 Receptor Agonists in Psoriasis and Other Skin Diseases: Insights From a Scoping Review and Mendelian Randomization Study","authors":"Xiafan Long,&nbsp;Yixuan Qiu,&nbsp;Zexu Lin,&nbsp;Yutong Liu,&nbsp;Jing Fang,&nbsp;Ye Wang,&nbsp;Yue Li,&nbsp;Yutong Sun,&nbsp;Shihan Zeng,&nbsp;Kai Huang","doi":"10.1155/dth/9612721","DOIUrl":"https://doi.org/10.1155/dth/9612721","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes and obesity, possess anti-inflammatory and tissue-reparative properties. Their dermatological relevance is increasingly recognized, but the available evidence remains heterogeneous and lacks integrated evaluation with exploratory genetic evidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To map the clinical evidence landscape of GLP-1RAs in skin diseases and to investigate the genetically predicted association between GLP-1 receptor (GLP-1R) signaling and dermatological outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed an updated scoping review of published clinical evidence integrated with a two-sample Mendelian randomization (MR) analysis. The MR analysis utilized large-scale plasma proteome genome-wide association study data (<i>n</i> = 35,559) and FinnGen datasets. Mediation analyses incorporating 1091 blood metabolites and 91 inflammatory proteins were conducted to explore potential underlying pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The updated scoping review included 113 published studies. Psoriasis/psoriatic disease, diabetic foot ulcers, and hidradenitis suppurativa represented major beneficial-effect categories, whereas cutaneous adverse events such as dermal hypersensitivity reactions and hair loss were also frequently reported. Building upon these clinical findings, our exploratory MR analysis showed that genetically predicted GLP-1R levels were nominally associated with lower psoriasis vulgaris risk (OR = 0.29; 95% CI = 0.10–0.80; <i>p</i> = 0.017). Mediation analysis suggested a potential overall association between GLP-1R and psoriasis risk (OR = 0.986; 95% CI = 0.976–0.997; <i>p</i> = 0.014), with possible mediation by metabolites including 3-hydroxydodecanedioate (mediation proportion, 6.8%) and the mannose-to-fructose ratio (5.3%), as well as the inflammatory protein interleukin-9 (−5.7%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This integrative study synthesizes evidence from a scoping review and exploratory genetic analysis, suggesting a potential protective association between GLP-1R signaling and psoriasis. The findings support further investigation of incretin-based strategies in psoriatic disease and provide hypothesis-generating genetic insights into potential metabolic and inflammatory mechanisms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9612721","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}